cellvie Inc., a Zurich, Switzerland- and Houston, TX-based Therapeutic Mitochondria Transplantation (TMT) company, closed a $5.5M financing.
The round was led by Taiho Ventures, with participation from existing investors Kizoo Technology Capital GmbH. Taiho Ventures will take a board seat.
The company intends to use the funds to get accelerate the development of its technology platform, strengthen the team, and further establish mitochondria manufacturing.
Led by Dr. Alexander Schueller, co-founder and CEO, and Dr. James McCully, cellvie employs proprietary preparation and delivery techniques to transplant mitochondria directly into compromised cells. The organelles penetrate the cell walls through endocytosis and merge with the mitochondrial network, to contribute to the cells’ energy metabolism.
FinSMEs
06/02/2023